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Abstract
Background: Campylobacter spp. are a common cause of mostly self-limiting enterocolitis. Although rare, pericarditis
and myopericarditis have been increasingly documented as complications following campylobacteriosis. Such cases
have occurred predominantly in younger males, and involved a single causative species, namely Campylobacter jejuni.
We report the first case of myopericarditis following Campylobacter coli enterocolitis, with illness occurring in an
immunocompetent middle-aged female.
Case presentation: A 51-yo female was admitted to a cardiology unit with a 3-days history of chest pain. The woman
had no significant medical history or risk factors for cardiac disease, nor did she report any recent overseas travel. Four
days prior to the commencement of chest pain the woman had reported onset of an acute gastrointestinal illness,
passing 3–4 loose stools daily, a situation that persisted at the time of presentation. Physical examination showed the
woman’s vital signs to be essentially stable, although she was noted to be mildly tachycardic. Laboratory testing showed
mildly elevated C-reactive protein and a raised troponin I in the absence of elevation of the serum creatinine kinase.
Electrocardiography (ECG) demonstrated concave ST segment elevations, and PR elevation in aVR and depression in lead
II. Transthoracic echocardiogram (TTE) revealed normal biventricular size and function with no significant valvular
abnormalities. There were no left ventricular regional wall motion abnormalities. No pericardial effusion was present but
the pericardium appeared echodense. A diagnosis of myopericarditis was made on the basis of chest pain, typical ECG
changes and troponin rise. The chest pain resolved and she was discharged from hospital after 2-days of observation,
but with ongoing diarrhoea. Following discharge, a faecal sample taken during the admission, cultured Campylobacter
spp. Matrix assisted laser desorption ionization time-of-flight (Bruker) confirmed the cultured isolate as C. coli.
Conclusion: We report the first case of myopericarditis with a suggested link to an antecedent Campylobacter coli
enterocolitis. Although rare, myopericarditis is becoming increasingly regarded as a complication following
campylobacteriosis. Our report highlights potential for pericardial disease beyond that attributed to Campylobacter jejuni.
However uncertainty regarding pathogenesis, coupled with a paucity of population level data continues to restrict
conclusions regarding the strength of this apparent association.
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Background
Campylobacter species are among the most widespread
and commonest cause of bacterial enterocolitis worldwide
[1]. C. jejuni is recognised as the leading cause of human
illness, although C. coli might account for up to 25% of
Campylobacter enterocolitis [2]. Complications such as
bacteraemia or the development of post-infectious sequelae
have an established place in the epidemiology of campylo-
bacteriosis, with cardiac complications being less com-
monly reported [1]. We describe what we believe to be the
first case of myopericarditis associated with C. coli entero-
colitis and discuss the epidemiology and pathogenesis of
this condition.
Case presentation
A 51-yo female was admitted to the cardiology unit of an
Australian public hospital with a 3-day history of continu-
ous, dull, non-radiating, non-pleuritic, left lateral chest
pain, with associated diaphoresis, nausea, palpitations and
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pre-syncope. Some relief of chest pain was achieved by
leaning forward. Administration of combined paracetamol
and codeine phosphate also relieved the pain. Four days
prior to the commencement of chest pain the woman had
reported onset of an acute gastrointestinal illness, passing
3–4 loose stools daily. This diarrhoea was persistent at the
time of presentation. The woman had no significant med-
ical history or risk factors for cardiac disease, nor did she
report any recent overseas travel.
Physical examination showed the woman to be afebrile
but mildly tachycardic, with a heart rate of 106 bpm.
Blood pressure was 120/76 mm Hg. Examination of the
chest revealed normal heart sounds, without any mur-
mur or rub. Jugular venous pressure was normal.
Pulmonary examination was normal with no signs of re-
spiratory distress (RR 18), although mild tachypnea was
noted during the course of her admission. The abdomen
was soft and non-tender.
Laboratory testing showed a mildly elevated C-reactive
protein (30.0 mg/L; normal range <5.0 mg/L) and a
raised troponin I (maximal value 70 ng/L at the time of
emergency department presentation; normal range <16)
in the absence of elevation of the serum creatinine
kinase. Liver enzymes were mildly elevated with an ALT
65 U/L (normal range <55 U/L) and ALKP 142 U/L
(normal range 20–110 U/L). Full blood count and serum
electrolytes were unremarkable.
Serial electrocardiographs demonstrated concave ST
segment elevations involving leads I, II, III, aVF and V6,
PR elevation in aVR and PR depression in lead II (Fig. 1).
Differential diagnoses of completed acute myocardial
infarction or pericarditis secondary to recent diarrhoeal
illness were made, with the woman initially managed for
an acute coronary syndrome with subcutaneous clexane
70 mg bd, aspirin 100 mg daily, clopidogrel 75 mg daily
and metoprolol 25 mg bd prior to expert cardiology
review and echocardiogram. Transthoracic echocardio-
gram (TTE) revealed normal biventricular size and func-
tion with no significant valvular abnormalities. No
pericardial effusion was present but the pericardium
appeared echodense and thickened. A diagnosis of myo-
pericarditis was made.
Clexane and clopidogrel were ceased and colchicine
500mcg bd commenced. The chest pain resolved and
she was discharged from hospital after 2 days, but with
ongoing diarrhoea. Following hospital discharge, a faecal
sample taken during the admission, cultured Campylo-
bacter spp. in isolation. Matrix assisted laser desorption
ionization time-of-flight (Bruker) confirmed the cultured
isolate as C. coli.
Discussion
Acute pericarditis is a not uncommon, frequently idio-
pathic disorder that mostly follows a benign clinical
course. Some myocardial involvement often accompanies
acute pericarditis, with the term myopericarditis indicat-
ing the pericardium as the primary focus [3]. Viruses are
often implicated when acute pericarditis or myopericardi-
tis are linked to infection, with bacterial causes less
commonly described [3]. Diagnostic criteria for acute peri-
carditis include chest pain, pericardial friction rub, ST seg-
ment elevations and pericardial effusion, with a clinical
diagnosis made when two of these criteria are met [3]. A
clinical diagnosis of myopericarditis includes the add-
itional detection of elevated cardiac enzymes or a new
onset of depressed left ventricular systolic function [3].
Fig. 1 Electrocardiogram of case patient showing ST segment elevations in leads I, II, III, aVF and V6 and PR segment depression in lead II
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Campylobacter spp. have an uncommon but increas-
ingly recognised link with myopericarditis, as supported
by a growing body of case reports and reviews of litera-
ture [4–6]. Our report is notable in terms of the
observed differences in both pathogen and host charac-
teristics. Firstly, our patient was positive for C. coli, a
species well recognised as a cause of enterocolitis, but
not previously reported in association with myopericar-
ditis. Secondly, the patient was a healthy, middle-aged
female, in contrast to previous patients where most were
younger immunocompetent males [4–6]. Although
Campylobacter does show tendency to cause higher
rates of disease in men compared to women, the appar-
ent predilection towards men in myopericarditis is strik-
ing. However despite this observation, epidemiological
evidence of a causal association between campylobacter-
iosis and myopericarditis is lacking. We identified a
single study that showed a greater incidence of myocar-
ditis in Campylobacter positive cases than controls at
16.1 cases per 100,000 person-years (95% CI 2.3–114.4)
compared to 1.6 cases per 100,000 person-years (95% CI
0.2–11.4), but the result was not significant and absolute
case numbers were small [7].
It is important to make distinction between myoperi-
carditis associated with C. jejuni or C. coli and that with
C. fetus. The former are recognised causes of enteric dis-
ease in humans and likely represent archetypal causes of
Campylobacter myopericarditis. Conversely C. fetus is an
atypical, invasive species, capable of evading the host im-
mune system by means of complement resistant surface
proteins [8]. As such it is more frequently isolated from
blood and pericardial fluid, with enteric symptoms either
absent or less pronounced [9]. For C. jejuni (and C. coli)
associated myopericarditis, the putative mechanisms
include direct infection of the pericardium or myocar-
dium, an immune hypersensitivity reaction, or the effect
of bacterial toxins [10]. Currently evidence for direct in-
fection is limited to two reports of C. jejuni detection in
pericardial fluid [11, 12]. A dominant immune-mediated
response also seems less likely given the short window
between the onset of enteric and cardiac symptoms, as
distinct to that seen with C. jejuni and development of
other immune-mediated disease (e.g., Guillain–Barré
syndrome and reactive arthritis) [10]. Although there is
a lack of evidence for a specific Campylobacter-associ-
ated cardiotoxin [13], the short window period surely
favors a toxin-mediated mechanism [4, 6]. Furthermore,
the infrequency of C. coli myopericarditis as highlighted
by our case might possibly be explained by the domin-
ance of C. jejuni at the species level, along with the
lower incidence of cytotoxin and enterotoxin production
by C. coli compared to C. jejuni [13].
It is unclear whether antibiotic treatment influences
the outcome of Campylobacter spp. myopericarditis,
however a recent examination of C. jejuni-associated
myopericarditis cases showed treatment with either
macrolide or fluoroquinolone antibiotics to be a com-
mon practice although without any apparent consensus
on dosage and treatment duration [5]. However campy-
lobacteriosis is generally regarded as a self-limiting
illness with antimicrobial therapy recommended for im-
munocompromised patients, patients whose symptoms
are severe or persistent, or who develop extra-intestinal
infections [1]. For our case confirmation of Campylobac-
ter spp. in stool occurred following hospital discharge,
with a mechanism for myopericarditis such as direct in-
fection or toxin-mediated response not able to be readily
determined. As such antimicrobial therapy was not
commenced. Treatment for the myopericarditis was
conservative, using nonsteroidal anti-inflammatory drugs
(NSAIDS) and colchicine. Among case reports describ-
ing Campylobacter-associated myopericarditis we identi-
fied a single episode where colchicine, as an adjunctive
to aspirin, was used in treating myopericarditis, with the
case reported as fully recovered at a 3-month review
[14]. Anecdotally, clinical outcomes for C. jejuni (and C.
coli) associated myopericarditis appear favourable [5]
with low rates of morbidity, mortality, evolution to heart
failure and worsening ventricular function [15].
Conclusion
We report the first case of myopericarditis linked to a C.
coli enterocolitis, with the illness running a benign clin-
ical course. While increasingly recognised as a complica-
tion of campylobacteriosis, the paucity of population
level data restricts further conclusions on the strength of
any association between Campylobacter infection and
myopericarditis. Further, the mechanism(s) of pathogen-
esis also remain uncertain, although anecdotally may
favour a toxin-mediated response.
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